<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588704</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO1001</org_study_id>
    <secondary_id>wsy002</secondary_id>
    <nct_id>NCT01588704</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma</brief_title>
  <official_title>A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Si-Yu Wang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prognosis of patients with unresectable, locally advanced non-small cell lung cancer
      (NSCLC) is poor. Chemoradiotherapy is the main treatment modality for this disease. The newer
      drug regimens can be expected to improve survival in this subset of NSCLC patients. Modern
      targeted therapies have enhanced the outcomes of lung cancer treatment, especially for
      advanced NSCLC. Among the targeted approaches for the inhibition of angiogenesis is
      bevacizumab, a monoclonal antibody that represses vascular endothelial growth factor (VEGF).
      Bevacizumab in combination with platinum-based chemotherapy used as neoadjuvant chemotherapy
      may change the previous treatment modality. It allows some lung cancer patients to be
      downstaged to surgery rather than radiotherapy. Thus, survival of these patients may be
      improved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigates the role of neoadjuvant pemetrexed, carboplatin and bevacizumab in
      unresectable, locally advanced lung adenocarcinoma.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resectability rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with perioperative complications</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant Bevacizumab</intervention_name>
    <description>Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection</description>
    <arm_group_label>Neoadjuvant Bevacizumab</arm_group_label>
    <other_name>Pemetrexed (Alimta)</other_name>
    <other_name>Bevacizumab (Avastin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed unresectable, locally advanced (III A (bulky N2), III B) lung
             adenocarcinoma

          -  No previous chemotherapy, radiotherapy, surgery or biological therapy for lung cancer

          -  Adequate organ and bone marrow function

        Exclusion Criteria:

          -  Prior chemotherapy or radiation therapy for NSCLC

          -  Prior treatment with bevacizumab or other agents specifically targeting vascular
             endothelial growth factor (VEGF)

          -  Patients with known hypersensitivity to other recombinant human antibodies

          -  History of stroke or transient ischemic attack (TIA).

          -  History of myocardial infarction or unstable angina within the past 12 months.

          -  Other serious illness or medical condition including unstable cardiac disease
             requiring treatment, history of significant neurologic or psychiatric disorders
             (including psychotic disorders, dementia, or seizures), symptomatic diverticulitis, or
             active uncontrolled infection.

          -  Women who are pregnant or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Si-Yu Wang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Si-Yu Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>lung adenocarcinoma</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>surgical resection rate</keyword>
  <keyword>safety</keyword>
  <keyword>feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

